---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-153075"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:50:31.177033+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics posts positive Phase 2 data for atumelnant; paltusotine NDA on track for 2H 2024

## Summary
- Atumelnant: 100% of CAH (n=6) achieved A4 below ULN; 100% of ADCS (n=5) normalized UFC at 80 mg once daily.
- Paltusotine: PATHFNDR-2 met primary endpoint – 56% on drug vs 5% placebo achieved IGF-1 ≤1.0xULN (p<0.0001).
- PATHFNDR-1 PRO analysis: paltusotine reduced breakthrough symptom exacerbations vs prior injectable SRLs.
- Long-term ACROBAT Advance: stable IGF-1, symptom control, and safety at up to 42 months.
- Crinetics expects to complete NDA submission for paltusotine in 2H 2024.

## SEC filing metadata
- accession: 0001193125-24-153075
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524153075/0001193125-24-153075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524153075/d823838d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-153075
- JSON: https://secwatch.observer/filing/0001193125-24-153075.json
- Plain text: https://secwatch.observer/filing/0001193125-24-153075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.